Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IONQ Inc (IONQ) vs Smith & Nephew plc (SNN) Price & Performance

Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

IONQ Inc vs Smith & Nephew plc — how do they compare? IONQ Inc trades at $44.99 (market cap $17.60B), while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: IONQ Inc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.65% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.

IONQSNN
Market Cap
$17.60B$12.54B
Sector
TechnologyHealth
52-Week High
$82.09$38.70
52-Week Low
$26.59$28.73
Enterprise Value
$15.53B$15.57B
Dividend Yield
2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IONQ Inc

IONQ trades at $45.20, up 6.28% today, with a bullish technical signal from moving averages and strong resistance near $46. The company reported Q2 2026 revenue growth of 287% to $80.1 million, though it missed EPS estimates. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism on quantum computing leadership.

Outlook is growth-driven but high-risk; revenue is projected to double in 2026, yet net losses exceed $1.4 billion. Key risks include profitability timeline, cash burn, and competitive pressures. Upside hinges on execution of its quantum roadmap and defense contracts, but volatility persists.

Smith & Nephew plc

SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.

The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IONQ Inc

IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.

Read more on IONQ

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN